title: Regulation of cardiac angiotensinogen mRNA in vivo and in vitro.
abstract: In this study, to investigate the mechanism of hypertension-associated induction of cardiac angiotensinogen in vivo and in vitro, we studied the regulation of angiotensinogen mRNA in the hearts of genetically hypertensive rats and in the rat cardiomyocytes. Levels of cardiac angiotensinogen mRNA were significantly increased in the hypertensive rats. Steady state mRNA levels for angiotensinogen mRNA in cardiomyocytes were increased by angiotensin II and mechanical stretch. The addition of an angiotensin II type 1 receptor antagonist (CV11974) and a transcriptional inhibitor (actinomycin D) completely blocked the induction of angiotensinogen mRNA by angiotensin II in cardiomyocytes. The addition of CV11974 significantly, but not completely, inhibited the induction of angiotensinogen mRNA by mechanical stretch. Actinomycin D completely blocked the induction of angiotensinogen mRNA by stretch in cardiomyocytes. An angiotensin II type 2 receptor antagonist (PD123319) and a protein synthesis inhibitor (cycloheximide) did not affect the induction. These results indicate that the expression of cardiac angiotensinogen mRNA is activated by the development of hypertensive cardiac hypertrophy, and that angiotensin II and mechanical stretch activates the angiotensinogen gene via the angiotensin II type 1 receptor-pathway in cardiomyocytes.
authors.affiliation: Second Department of Internal Medicine, Yokohama City University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tamura
authors.forename: S
authors.initials: S
authors.lastname: Umemura
authors.forename: N
authors.initials: N
authors.lastname: Nyui
authors.forename: K
authors.initials: K
authors.lastname: Hibi
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Sumida
authors.forename: T
authors.initials: T
authors.lastname: Ishigami
authors.forename: M
authors.initials: M
authors.lastname: Kihara
authors.forename: M
authors.initials: M
authors.lastname: Yabana
authors.forename: N
authors.initials: N
authors.lastname: Takagi
authors.forename: M
authors.initials: M
authors.lastname: Ishii
mesh_terms: D000808:Angiotensinogen / Q000378:metabolism*; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D002478:Cells, Cultured; D003609:Dactinomycin / Q000494:pharmacology; D006973:Hypertension / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D013314:Stress, Mechanical; D013777:Tetrazoles / Q000494:pharmacology; D014158:Transcription, Genetic; D015854:Up-Regulation
chemical_list: D001562:Benzimidazoles; D001713:Biphenyl Compounds; D019384:Nucleic Acid Synthesis Inhibitors; D012333:RNA, Messenger; D013777:Tetrazoles; D000808:Angiotensinogen; D003609:Dactinomycin; C081643:candesartan